The British molecular diagnostics firm recently completely a redesign of its point-of-care system, called Q-POC, and is planning to seek a CE-IVD mark for the device later this year.
The money is being provided under three Genome Canada funding competitions in partnership with the Canadian federal government and other groups.
Formerly known as SlipChip Corp, the firm has recently won nearly $10 million in funding to hone its approaches to sepsis and CT/NG testing.
The company has built a small and rugged system boasting 20-minute qPCR reactions and plans to expand the platform for other types of diagnostics.
The non-profit group is interested in improving manufacturing efficiencies to make point-of-care diagnostics more accessible.
Twelve hospitals will use the company's assays to screen vulnerable patients for genes from multi-drug resistant organisms.
Researchers hope to advance the technology to support an assay to help personalize oral cancer treatment by avoiding the development of mucositis.
The partners will leverage IME's rare cell isolation technology, a microchip containing a microfabricated filter membrane to isolate and enrich fetal cells from maternal blood.
The portable analyzer runs an RT-qPCR-based Ebola assay and takes about 75 minutes to detect the presence of the virus from whole blood.
NEW YORK (GenomeWeb News) – Molecular diagnostics company Rheonix today announced a joint development agreement with Life Technologies aimed at a molecular testing platform for the applied markets.
NPR reports that researchers in Italy are testing a gene drive aimed at controlling mosquito populations.
Researchers may experience the effects of the government shutdown for a while, the Los Angeles Times reports.
A new study finds that the majority of patients at a Tijuana clinic received a diagnosis after first-line genome sequencing, the San Diego Union-Tribune reports.
In Genome Biology this week: post-transcriptional modification-based stratification of glioblastoma, single-cell analysis of gene expression and methylation in human iPSCs, and more.